Publikationen in Zusammenarbeit mit Forschern von Fundación Jiménez Díaz (28)

2023

  1. Distinct GSDMB protein isoforms and protease cleavage processes differentially control pyroptotic cell death and mitochondrial damage in cancer cells

    Cell Death and Differentiation, Vol. 30, Núm. 5, pp. 1366-1381

  2. High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer

    International journal of molecular sciences, Vol. 24, Núm. 4

  3. Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 2, pp. 389-400

  4. miR-146a-5p Promotes Angiogenesis and Confers Trastuzumab Resistance in HER2+ Breast Cancer

    Cancers, Vol. 15, Núm. 7

2022

  1. Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer

    Science Advances, Vol. 8, Núm. 20

  2. mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer

    Molecular Cancer Research, Vol. 20, Núm. 7, pp. 1108-1121

  3. miR-99a-5p modulates doxorubicin resistance via the COX-2/ABCG2 axis in triple-negative breast cancer: from the discovery to in vivo studies

    Cancer Communications

2021

  1. Preclinical and clinical characterization of fibroblast-derived neuregulin-1 on trastuzumab and pertuzumab activity in HER2-positive breast cancer

    Clinical Cancer Research, Vol. 27, Núm. 18, pp. 5096-5108

2020

  1. Autocrine CCL5 effect mediates trastuzumab resistance by ERK pathway activation in HER2-positive breast cancer

    Molecular Cancer Therapeutics, Vol. 19, Núm. 8, pp. 1696-1707

  2. FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease

    Journal of Clinical Investigation, Vol. 130, Núm. 9, pp. 4871-4887

  3. The hippo pathway transducers yap1/tead induce acquired resistance to trastuzumab in her2-positive breast cancer

    Cancers, Vol. 12, Núm. 5

  4. Tumor-associated fibroblasts promote HER2-targeted therapy resistance through FGFR2 activation

    Clinical Cancer Research, Vol. 26, Núm. 6, pp. 1432-1448

2019

  1. NK cell infiltrates and HLA class I expression in primary HER2 þ breast cancer predict and uncouple pathological response and disease-free survival

    Clinical Cancer Research, Vol. 25, Núm. 5, pp. 1535-1545

  2. Detection of breast cancer stem cell gene mutations in circulating free DNA during the evolution of metastases

    Breast Cancer Research and Treatment, Vol. 178, Núm. 2, pp. 251-261

  3. Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion

    European Journal of Cancer, Vol. 120, pp. 54-64

  4. High numbers of circulating CD57+ NK cells associate with resistance to her2-specific therapeutic antibodies in HER2+ primary breast cancer

    Cancer Immunology Research, Vol. 7, Núm. 8, pp. 1280-1292

  5. The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors

    Scientific Reports, Vol. 9, Núm. 1

2018

  1. MSK1 regulates luminal cell differentiation and metastatic dormancy in ER + breast cancer

    Nature Cell Biology, Vol. 20, Núm. 2, pp. 211-221

  2. Erratum to: MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer (Nature Cell Biology, (2018), 20, 2, (211-221), 10.1038/s41556-017-0021-z)

    Nature Cell Biology

  3. Recent insights into the development of preclinical trastuzumab-resistant HER2+ breast cancer models

    Current Medicinal Chemistry, Vol. 25, Núm. 17, pp. 1976-1998